Literature DB >> 25264128

Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.

G H Genzel1, W Stubbings2, C S Stîngu3, H Labischinski2, R Schaumann3.   

Abstract

The activity of finafloxacin against 73 strains of the Bacteroides fragilis group, 10 other Gram-negative anaerobic rods and 31 Clostridium difficile strains was determined by the broth microdilution technique. The activity was compared with that of moxifloxacin, levofloxacin, ciprofloxacin, clindamycin, imipenem, piperacillin/tazobactam and metronidazole. MIC(50/90) values (minimum inhibitory concentration, in μg/mL, at which 50% and 90% of the isolates tested are inhibited, respectively) for finafloxacin for the different species were determined: B. fragilis group, 0.5/2; other Gram-negative rods, 0.06/0.25; and C. difficile, 4/16. Furthermore, the MICs against 11 selected B. fragilis strains were determined under acidic conditions and resulted in MIC(50/90) values for finafloxacin of 0.25/4 μg/mL. Thus, finafloxacin shows promising activity against several pathogenic species of anaerobes. Furthermore, finafloxacin has increased activity against selected B. fragilis strains under acidic conditions compared with activity at neutral pH.
Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Anaerobic bacteria; Finafloxacin; Investigational fluoroquinolone

Mesh:

Substances:

Year:  2014        PMID: 25264128     DOI: 10.1016/j.ijantimicag.2014.07.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  2 in total

Review 1.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

Review 2.  Finafloxacin: first global approval.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.